| Association analysis identifies 65 new breast cancer risk loci K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ... Nature 551 (7678), 92-94, 2017 | 1433 | 2017 |
| Polygenic risk scores for prediction of breast cancer and breast cancer subtypes N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ... The American Journal of Human Genetics 104 (1), 21-34, 2019 | 999 | 2019 |
| Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ... The Lancet Oncology 21 (11), 1413-1422, 2020 | 688 | 2020 |
| Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ... Jama 313 (13), 1347-1361, 2015 | 583 | 2015 |
| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ... Nature genetics 49 (12), 1767-1778, 2017 | 398 | 2017 |
| Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses H Zhang, TU Ahearn, J Lecarpentier, D Barnes, J Beesley, G Qi, X Jiang, ... Nature genetics 52 (6), 572-581, 2020 | 364 | 2020 |
| Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ... PLoS genetics 9 (3), e1003212, 2013 | 340 | 2013 |
| A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer L Wu, W Shi, J Long, X Guo, K Michailidou, J Beesley, MK Bolla, XO Shu, ... Nature genetics 50 (7), 968-978, 2018 | 231 | 2018 |
| Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial) M Provencio, R Serna-Blasco, E Nadal, A Insa, MR García-Campelo, ... Journal of Clinical Oncology 40 (25), 2924-2933, 2022 | 227 | 2022 |
| Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer M Provencio, E Nadal, JL González-Larriba, A Martínez-Martí, R Bernabé, ... New England Journal of Medicine 389 (6), 504-513, 2023 | 198 | 2023 |
| Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes L Fachal, H Aschard, J Beesley, DR Barnes, J Allen, S Kar, KA Pooley, ... Nature genetics 52 (1), 56-73, 2020 | 167 | 2020 |
| Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing C Pérez-Barrios, I Nieto-Alcolado, M Torrente, C Jiménez-Sánchez, ... Translational lung cancer research 5 (6), 665, 2016 | 164 | 2016 |
| Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ... Free Radical Biology and Medicine 135, 167-181, 2019 | 135 | 2019 |
| Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring D Pérez-Callejo, A Romero, M Provencio, M Torrente Translational lung cancer research 5 (5), 455, 2016 | 115 | 2016 |
| Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ... Free Radical Biology and Medicine 130, 163-173, 2019 | 112 | 2019 |
| Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium M Colombo, MJ Blok, P Whiley, M Santamarina, S Gutierrez-Enriquez, ... Human molecular genetics 23 (14), 3666-3680, 2014 | 107 | 2014 |
| Assessment of topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization A Romero, M Martín, MCU Cheang, JAL García-Asenjo, B Oliva, X He, ... The American journal of pathology 178 (4), 1453-1460, 2011 | 102 | 2011 |
| Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer M Martin, A Romero, MCU Cheang, JA López García-Asenjo, ... Breast cancer research and treatment 128, 127-136, 2011 | 93 | 2011 |
| Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients A Romero, JA García-Sáenz, M Fuentes-Ferrer, JAL Garcia-Asenjo, ... Annals of oncology 24 (3), 655-661, 2013 | 80 | 2013 |
| Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging JA García-Saenz, P Ayllón, M Laig, D Acosta-Eyzaguirre, ... BMC cancer 17, 1-8, 2017 | 77 | 2017 |
Mariano ProvencioHospital Universitario Puerta de Hierro. Universidad Autónoma de Madrid.在 salud.madrid.org 的电子邮件经过验证
